TRPV3 and inflammatory skin disease: Preclinical studies have provided a certain rationale to support the development of TRPV3 antagonists for the treatment of inflammatory skin diseases, pruritus and pain.583 However, to date, only one TRPV3 inhibitor (GRC15300) has entered clinical trial targeting osteoarthritis and neuropathic pain.584 Moreover, by the end of 2013, these trials were discontinued.